يعرض 1 - 10 نتائج من 60 نتيجة بحث عن '"Cruz-Jurado, Josefina"', وقت الاستعلام: 1.04s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية

    المساهمون: S. Hidalgo-Río, J. Carrillo-García, D.S. Moura, S. Stacchiotti, A. López-Pousa, A. Redondo, A. Italiano, A. Gutiérrez, G. Grignani, N. Hindi, J. López-Guerrero, X.G.D. Muro, J.M. Trufero, E. Palmerini, A.S. García, D. Bernabeu, A. Le Cesne, P.G. Casali, J. Blay, J. Cruz Jurado, J. Martin-Broto

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36077723; info:eu-repo/semantics/altIdentifier/wos/WOS:000851101900001; volume:14; issue:17; firstpage:1; lastpage:12; numberofpages:12; journal:CANCERS; https://hdl.handle.net/2434/945830Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85137793961

  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية

    العلاقة: https://doi.org/10.3390/cancers13215432Test; Cruz-Merino, L., Gion, M., Cruz-Jurado, J., Quiroga, V., Andrés, R., Moreno, F., Alonso-Romero, J., Ramos, M., Holgado, E., Cortés, J., López-Miranda, E., Henao-Carrasco, F., Palazón-Carrión, N., Rodríguez, L., Ceballos, I., Casas, M., Benito, S., Chiesa, M., Bezares, S., … Rojo, F. (2021). Pembrolizumab plus gemcitabine in the subset of triple-negative advanced breast cancer patients in the geicam/2015-04 (Pangea-breast) study. Cancers, 13(21), 5432. https://doi.org/10.3390/cancers13215432Test; http://hdl.handle.net/11268/12149Test

  6. 6
    دورية أكاديمية

    مصطلحات موضوعية: Sarcoma, Guidelines, Soft-tissue tumors, Uncommon tumors

    وصف الملف: application/pdf

    العلاقة: Clinical & Translational Oncology; Vol. 23 Núm. 5 (may 2021), p. 922-930; https://ddd.uab.cat/record/271999Test; urn:10.1007/s12094-020-02534-0; urn:oai:ddd.uab.cat:271999; urn:scopus_id:85099064154; urn:articleid:16993055v23n5p922; urn:pmid:33405052; urn:pmc-uid:8057970; urn:pmcid:PMC8057970; urn:oai:pubmedcentral.nih.gov:8057970

  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية

    المساهمون: Institut Català de la Salut, de la Cruz-Merino L Medical Oncology Department, Virgen Macarena University Hospital, Medicine Department University of Seville, Seville, Spain. GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Gion M GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. Cruz-Jurado J GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain. Quiroga V GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Badalona Applied Research Group in Oncology (B-ARGO Group), Catalan Institute of Oncology, Badalona, Spain. Andrés R GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain. Moreno F GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. Medical Oncology Department, Hospital Clínico Universitario San Carlos, Madrid, Spain. Cortés J GEICAM Spanish Breast Cancer Group, San Sebastián de los Reyes, Spain. International Breast Cancer Center (IBCC), Quirón Teknon Hospital (Quironsalud Group), Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain, Vall d'Hebron Barcelona Hospital Campus

    المصدر: Scientia

    وصف الملف: application/pdf

    العلاقة: Cancers;13(21); https://doi.org/10.3390/cancers13215432Test; Cruz-Merino L de la, Gion M, Cruz-Jurado J, Quiroga V, Andrés R, Moreno F, et al. Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers. 2021 Oct 29;13(21):5432.; https://hdl.handle.net/11351/7621Test; 000719460800001

  9. 9
    دورية أكاديمية

    المساهمون: Martínez-Trufero,J, Gurruchaga-Sotes,I Javier Martinez-Trufero, Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain. De Sande-González,LM Medical Oncology Department, Complejo Asistencial Universitario de Leon, Leon, Spain. Luna,P Medical Oncology Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. Martin-Broto,J Medical Oncology Department, Hospital Universitario Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. Álvarez,R Medical Oncology Department, Hospital Universitario Gregorio Marañon, Madrid, Spain. Marquina,G Medical Oncology Department, Hospital Universitario Clinico San Carlos, Madrid, Spain. Diaz-Beveridge,R Medical Oncology Department, Hospital Politécnico La Fe, Valencia, Spain. Poveda,A Medical Oncology Department, Instituto Valenciano de Oncologia, Valencia, Spain. Cano,JM Medical Oncology Department, Hospital General de Ciudad Real, Ciudad Real, Spain. Cruz-Jurado,J Medical Oncology Department, Hospital Universitario Canarias, Santa Cruz de Tenerife, Spain. López Pousa,A Medical Oncology Department, Hospital Universitario Santa Creu i Sant Pau, Barcelona, Spain. Vaz Salgado,MA Medical Oncology Department, Hospital Universitario Ramon y Cajal, RYCIS, CIBERONC, Madrid, Spain. Valverde-Morales,C Medical Oncology Department, Hospital Universitario Vall D’Hebron, Barcelona, Spain. Sevilla,I Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Medical Oncology Department, Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Malaga, Spain. Martínez-García,J Medical Oncology Department, Hospital Virgen de la Arrixaca, Murcia, Spain. Rubio-Casadevall,J Medical Oncology Department, Instituto Catalan Oncologia, Girona, Spain. De Juan,A Medical Oncology Department, Hospital Marqués de Valdecilla, Santander, Spain. Carrasco,JA Medical Oncology Department, Hospital Alvaro Cunqueiro, Vigo, Spain. Moura,DS Instituto de Biomedicina de Sevilla (IBiS, CSIC, US, HUVR), Sevilla, Spain. Gutiérrez,A Hematology Department, Hospital Universitario Son Espases, 07010 Palma de Mallorca, Spain., This research was funded by the Spanish Group for Research on Sarcoma (grant number: NA) and partially by PharmaMar. PharmaMar S.A. did not have any role in study design, or in collection, analysis and interpretation of data.

    وصف الملف: application/pdf

    العلاقة: https://www.mdpi.com/2072-6694/13/4/792Test; Martínez-Trufero J, De Sande-González LM, Luna P, Martin-Broto J, Álvarez R, Marquina G, et al. A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study. Cancers. 2021 Feb 14;13(4):792; http://hdl.handle.net/10668/4498Test; PMC7917652

  10. 10
    دورية أكاديمية

    المساهمون: Sanfilippo, Roberta, Hindi, Nadia, Cruz Jurado, Josefina, Blay, Jean-Yve, Lopez-Pousa, Antonio, Italiano, Antoine, Alvarez, Rosa, Gutierrez, Antonio, Rincón-Perez, Inmaculada, Sangalli, Claudia, Pérez Aguiar, Jose Lui, Romero, Jesú, Morosi, Carlo, Sunyach, Marie-Pierre, Fabbroni, Chiara, Romagosa, Cleofe, Ranchere-Vince, Dominique, Dei Tos, Angelo P, Casali, Paolo G, Martin-Broto, Javier, Gronchi, Alessandro

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/36995731; info:eu-repo/semantics/altIdentifier/wos/WOS:000961089300002; journal:JAMA ONCOLOGY; https://hdl.handle.net/11577/3473858Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85159763666